<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356742</url>
  </required_header>
  <id_info>
    <org_study_id>DA1229_DMTD2_III</org_study_id>
    <nct_id>NCT04356742</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control</brief_title>
  <official_title>A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of dapagliflozin in the treatment of type 2 diabetes with
      metformin and evogliptin combination therapy. Half of subjects will receive dapagliflozin,
      metformin and evogliptin, while the other half will receive placebo, metformin and
      evogliptin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from the baseline in HbA1c (%) after 24 weeks</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline in fasting plasma glucose(mg/dL) after 24 weeks</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline in HbA1c response rate(&lt;7.0%, &lt;6.5%) after 24 weeks</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline in weight after 24 weeks</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin 10mg + Evogliptin 5mg + Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin Placebo + Evogliptin 5mg + Metformin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg</intervention_name>
    <description>Dapagliflozin 10mg, orally, once daily, up to 24weeks</description>
    <arm_group_label>Dapagliflozin 10mg + Evogliptin 5mg + Metformin</arm_group_label>
    <other_name>Forxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dapagliflozin Placebo, orally, once daily, up to 24weeks</description>
    <arm_group_label>Dapagliflozin Placebo + Evogliptin 5mg + Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evogliptin 5mg</intervention_name>
    <description>Evogliptin 5mg, orally, once daily for background therapy</description>
    <arm_group_label>Dapagliflozin 10mg + Evogliptin 5mg + Metformin</arm_group_label>
    <arm_group_label>Dapagliflozin Placebo + Evogliptin 5mg + Metformin</arm_group_label>
    <other_name>Suganon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin≥1000mg</intervention_name>
    <description>Metformin≥1000mg, orally, daily for background therapy</description>
    <arm_group_label>Dapagliflozin 10mg + Evogliptin 5mg + Metformin</arm_group_label>
    <arm_group_label>Dapagliflozin Placebo + Evogliptin 5mg + Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with type II diabetes mellitus aged 19 years or older

          2. Patients who had taken metformin(≥1000mg/day) and DPP(dipeptidyl peptidase)-4
             inhibitor combination therapy(or complex is allowed) at the same dose for at least 8
             weeks prior to the screening visit

          3. Patients with fasting plasma glucose≤250mg/dL at the screening visit

          4. Patients with 18.5kg/m^2≤BMI≤40kg/m^2 at the screening visit

          5. Patients who have signed an informed consent themselves after receiving detailed
             explanation about the clinical study

        Exclusion Criteria:

          1. Patients with type 1 diabetes, secondary diabetes, gestational diabetes, diabetic coma
             or -pre-coma, metabolic acidosis including lactic acidosis and diabetic ketoacidosis

          2. Patients with a medical history of New York Heart Association(NYHA) class III~IV heart
             failure or with congestive heart failure, acute and unstable heart failure

          3. Patients with severe infectious disease or severe traumatic systemic disorders

          4. Patients with hypopituitarism or adrenal insufficiency, pulmonary infarction, severe
             pulmonary dysfunction and other hypoxemia

          5. Patients with galactose intolerance, lapp lactase deficiency, glucose-galactose
             malabsorption

          6. Patients with moderate to severe stage renal disease, end stage renal disease,
             dialysis at the time of screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sung</last_name>
    <phone>+82-2-920-8369</phone>
    <email>jhsung@donga.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Catholic University of Korea Bucheon St. Mary's Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoo</last_name>
      <email>sjyoo@catholic.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

